Literature DB >> 646216

Relationships among digital clubbing, disease severity, and serum prostaglandins F2alpha and E concentrations in cystic fibrosis patients.

R J Lemen, A J Gates, A A Mathé, W W Waring, A L Hyman, P D Kadowitz.   

Abstract

Nine patients with cystic fibrosis but without digital clubbing (Group A) were matched, prospectively, by sex and approximate age to 9 cystic fibrosis patients with digital clubbing (Group B) and to 9 normal persons (control subjects). Patients in Group B had significantly (P less than 0.05) lower clinical scores and forced vital capacity than did those in Group A, indicating more severe pulmonary disease in the former; however, other spirometer tests of pulmonary function revealed no differences between Groups A and B. The degree of digital clubbing had significant (P less than 0.05) linear relationships to forced vital capacity (r = -0.73) and clinical scores (r = 0.853) for Groups A and B. Plasma concentrations of prostaglandins F2alpha and E were significantly increased (P less than 0.05) in both Group A (X +/- SE, 0.48 +/- 0.03 and 0.87 +/- 0.10 ng per ml, respectively) and Group B (X +/- SE, 0.68 +/- 0.04 and 1.81 +/- 0.16 ng per ml, respectively) compared to the control group (X +/- SE, 0.14 +/- 0.01 and 0.39 +/- 0.02 ng per ml, respectively). Group B had significantly larger concentrations than did Group A; however, plasma concentrations of prostaglandin 15-keto-13, 14-dihydro metabolite were not different in Groups A and B, and were significantly smaller than in the control group. These studies suggest that the degree of digital clubbing in cystic fibrosis is related to the severity of the pulmonary involvement and that the prostaglandin system may play an important role in this disease.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 646216     DOI: 10.1164/arrd.1978.117.4.639

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  8 in total

1.  Finger clubbing in cystic fibrosis.

Authors:  T J Pitts-Tucker; M G Miller; J M Littlewood
Journal:  Arch Dis Child       Date:  1986-06       Impact factor: 3.791

2.  Corticosteroid treatment in cystic fibrosis.

Authors:  J F Price; P Greally
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

3.  Gynaecomastia in cystic fibrosis.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-14

4.  Postoperative regression of clubbing at an unexpected rate in a patient with aortic and mitral valve replacement due to infective endocarditis.

Authors:  B Ozdemir; T Sentürk; A A Kaderli; M Keçebaş; S Güllülü; I Baran; O Ozdabakoğlu; A Aydinlar
Journal:  Ir J Med Sci       Date:  2008-10-09       Impact factor: 1.568

5.  Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis.

Authors:  J Roca-Ferrer; L Pujols; S Gartner; A Moreno; F Pumarola; J Mullol; N Cobos; C Picado
Journal:  Thorax       Date:  2006-03-03       Impact factor: 9.139

6.  Indomethacin therapy for hypertrophic pulmonary osteoarthropathy in patients with bronchogenic carcinoma.

Authors:  F W Leung; A J Williams; P Fan
Journal:  West J Med       Date:  1985-03

7.  Structural and biochemical changes in lungs of 3-methylindole-treated rats.

Authors:  L W Woods; D W Wilson; M J Schiedt; S N Giri
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

Review 8.  Abnormal unsaturated fatty acid metabolism in cystic fibrosis: biochemical mechanisms and clinical implications.

Authors:  Adam C Seegmiller
Journal:  Int J Mol Sci       Date:  2014-09-11       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.